BenevolentAI has teamed up with Action Against AMD* to find treatments and a potential cure for age-related macular degeneration, the leading cause of blindness in the UK.
British artificial intelligence group BenevolentAI has signed an exclusive license with Johnson & Johnson group Janssen, picking up rights to a series of its novel clinical stage drug candidates.